Abbott Laboratories
ABT131.870USD
Today
-1.39%
5 Days
-0.80%
1 Month
+2.00%
6 Months
+4.07%
Year to Date
+16.59%
1 Year
+13.29%
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
Score Analysis
Analyst Rating
Company Highlights
Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.
Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.
News
Abbott beats quarterly profit estimates on medical devices demand
July 17 (Reuters) - Abbott ABT.N beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its medical devices including continuous glucose monitors.
Trump Plans Major Drug Price Cuts, Pharma Stocks Tumbles
Trump signals an executive order to slash drug prices, causing a sharp sell-off in Asian pharmaceutical stocks. Major companies like Johnson & Johnson, Pfizer, and Abbott could be hit hard.
.jpg)
How Artificial Intelligence Benefits Health Care: 10 AI Healthcare Stocks to Watch
TradingKey - With the rapid development of artificial intelligence (AI), beyond the well-known large language models such as ChatGPT and DeepSeek, people are continuously exploring new AI applications and investigating how the cutting-edge technologies driving the "Fourth Industrial Revolution"...
Abbott Laboratories falls on Q1 profit forecast below estimates
Shares of medical device maker Abbott Laboratories ABT.N fall 2.02% to $114.43 premarket.Co expects Q1 adj EPS of between $1.05 and $1.09, below estimates of $1.11 - data compiled by LSEG. Forecasts 2025 adj EPS of $5.05 to $5.25, with midpoint mostly in line with estimates of $5.16...
Financial Indicators
EPS
Total revenue
Company
Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.
Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.
Related Instruments
